Targeted therapy in multiple myeloma (Q36108614)

12 August 2017

1 reference

title

Targeted therapy in multiple myeloma (English)

1 reference

12 August 2017

Wee Joo Chng

1

1 reference

12 August 2017

Lee Gong Lau

series ordinal

2

1 reference

12 August 2017

Noorainun Yusof

series ordinal

3

1 reference

12 August 2017

Benjamin M F Mow

series ordinal

4

1 reference

12 August 2017

publication date

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

12

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

91-104

1 reference

Multiple myeloma: evolving genetic events and host interactions

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Multiple myeloma: almost all patients are cytogenetically abnormal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

New drugs for treatment of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

New insights into role of microenvironment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide in refractory and relapsing multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide for previously untreated indolent or smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide as initial therapy for early-stage myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Thalidomide, deep venous thrombosis and vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Arterial thrombosis in four patients treated with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Clinical activity of arsenic trioxide for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Apoptosis: a link between cancer genetics and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200204

10.1177/107327480501200204

21 January 2018

Identifiers

DOI

0 references

1 reference